389 related articles for article (PubMed ID: 34461271)
21. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
Holstein SA; Grant SJ; Wildes TM
J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
[TBL] [Abstract][Full Text] [Related]
22. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.
Khanam R; Faiman B; Batool S; Najmuddin MM; Usman R; Kuriakose K; Ahmed A; Rehman MEU; Roksana Z; Syed Z; Anwer F; Raza S
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685606
[TBL] [Abstract][Full Text] [Related]
23. Effective anti-BCMA retreatment in multiple myeloma.
Gazeau N; Beauvais D; Yakoub-Agha I; Mitra S; Campbell TB; Facon T; Manier S
Blood Adv; 2021 Aug; 5(15):3016-3020. PubMed ID: 34351389
[TBL] [Abstract][Full Text] [Related]
24. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
[TBL] [Abstract][Full Text] [Related]
25. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
26. Quad-class exposed/refractory myeloma is associated with short survival.
Piron B; Costes-Tertrais D; Gastinne T; Fourmont AM; Dubruille V; Blin N; Moreau P; Touzeau C; Tessoulin B
Br J Haematol; 2024 Jan; 204(1):186-190. PubMed ID: 37833834
[TBL] [Abstract][Full Text] [Related]
27. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
Springer C; Krauter J; Trummer A
Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
[TBL] [Abstract][Full Text] [Related]
28. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya H; Sidana S
Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
[TBL] [Abstract][Full Text] [Related]
30. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Paul B; Rodriguez C; Usmani SZ
Drugs; 2022 Apr; 82(6):613-631. PubMed ID: 35412114
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma.
Kapinos KA; Hu E; Trivedi J; Geethakumari PR; Kansagra A
Cancer Control; 2023; 30():10732748221142945. PubMed ID: 36651055
[TBL] [Abstract][Full Text] [Related]
33. Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Raab MS; Cohen YC; Schjesvold F; Aardalen K; Oka A; Spencer A; Wermke M; Souza AD; Kaufman JL; Cafro AM; Ocio EM; Doki N; Henson K; Trabucco G; Carrion A; Bender FC; Juif PE; Fessehatsion A; Fan L; Stonehouse JP; Blankenship JW; Granda B; De Vita S; Lu H
Leukemia; 2023 Jun; 37(6):1349-1360. PubMed ID: 37024520
[TBL] [Abstract][Full Text] [Related]
34. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
35. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
36. "Off-the-shelf" immunotherapies for multiple myeloma.
Mohammed T; Mailankody S
Semin Oncol; 2022 Feb; 49(1):60-68. PubMed ID: 35123801
[TBL] [Abstract][Full Text] [Related]
37. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
38. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
39. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
40. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
